PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cardiovascular Diabetology10.1186/s12933-014-0142-72014131Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonistsFrancisco Kerr Saraiva, Andrei C Spositohttp://link.springer.com/article/10.1186/s12933-014-0142-7/fulltext.html, http://link.springer.com/content/pdf/10.1186/s12933-014-0142-7.pdf, http://link.springer.com/content/pdf/10.1186/s12933-014-0142-7
Cardiovascular Research10.1093/cvr/cvy124201811410e70-e71Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCELSigne Sørensen Torekovhttp://academic.oup.com/cardiovascres/article-pdf/114/10/e70/25195498/cvy124.pdf
Cardiovascular Research10.1093/cvr/cvz32320191165916-930Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomesValerie D Heuvelman, Daniël H Van Raalte, Mark M Smitshttp://academic.oup.com/cardiovascres/advance-article-pdf/doi/10.1093/cvr/cvz323/31496575/cvz323.pdf, http://academic.oup.com/cardiovascres/article-pdf/116/5/916/32969246/cvz323.pdf, http://academic.oup.com/cardiovascres/article-pdf/116/5/916/32969246/cvz323.pdf
Journal of Diabetes Investigation10.1111/j.2040-1124.2012.00241.x201236490-491Glucagon-like peptide-1 receptor agonists and their effects on weight reductionShyi-Jang Shinhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.2040-1124.2012.00241.x, http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.2040-1124.2012.00241.x/fullpdf
Medical Council10.21518/2079-701x-2019-21-189-197202021189-197Organoprotective effects of glucagon-like peptide-1 receptor agonists with regard to findings of evidencebased cardiovascular safety studiesYu. Sh. Khalimov, V. G. Kuzmichhttps://www.med-sovet.pro/jour/article/viewFile/5493/5012
Endocrinology and Metabolism10.3803/enm.2016.31.2.2582016312258Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor AgonistsYu Mi Kang, Chang Hee Junghttp://synapse.koreamed.org/pdf/10.3803/EnM.2016.31.2.258, http://synapse.koreamed.org/DOIx.php?id=10.3803/EnM.2016.31.2.258, http://synapse.koreamed.org/DOIx.php?id=10.3803/EnM.2016.31.2.258
Cardiovascular Diabetology10.1186/s12933-018-0731-y2018171Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trialsAtsushi Tanaka, Koichi Nodehttp://link.springer.com/content/pdf/10.1186/s12933-018-0731-y.pdf, http://link.springer.com/article/10.1186/s12933-018-0731-y/fulltext.html, http://link.springer.com/content/pdf/10.1186/s12933-018-0731-y.pdf
10.21203/rs.2.16671/v22019Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of double-blind, randomized, placebo-controlled clinical trialsJing Qin, Li Songhttps://www.researchsquare.com/article/rs-7309/v2, https://www.researchsquare.com/article/rs-7309/v2.html
The Lancet Diabetes & Endocrinology10.1016/s2213-8587(15)00256-9201539667-669Cardiovascular safety of albiglutide and other glucagon-like peptide-1 receptor agonistsAndré J Scheenhttps://api.elsevier.com/content/article/PII:S2213858715002569?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S2213858715002569?httpAccept=text/plain
10.21203/rs.2.16671/v32020Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of double-blind, randomized, placebo-controlled clinical trialsJing Qin, Li Songhttps://www.researchsquare.com/article/rs-7309/v3, https://www.researchsquare.com/article/rs-7309/v3.html